Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Benitec Biopharma Limited (BNTC) had Return on Tangible Equity of -25.73% for the most recently reported fiscal year, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-45.55M |
|
-- |
|
-- |
|
$51.19M |
|
$-51.19M |
|
$5.65M |
|
$-45.55M |
|
$-45.55M |
|
$-45.55M |
|
$-45.55M |
|
$-45.55M |
|
$-45.55M |
|
$-51.19M |
|
$-51.13M |
|
46.56M |
|
46.56M |
|
$-0.98 |
|
$-0.98 |
|
| Balance Sheet Financials | |
$181.69M |
|
$0.18M |
|
$0.94M |
|
$182.62M |
|
$5.34M |
|
$0.27M |
|
$0.27M |
|
$5.61M |
|
$177.01M |
|
$177.01M |
|
$177.01M |
|
34.42M |
|
| Cash Flow Statement Financials | |
$-16.52M |
|
$-0.10M |
|
$98.98M |
|
$97.86M |
|
$180.09M |
|
$82.23M |
|
$26.41M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
34.00 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.62M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-25.73% |
|
|
Return on Tangible Equity |
-25.73% |
-24.94% |
|
-25.69% |
|
$5.14 |
|
$-0.36 |
|
$-0.35 |
|